12 [3] P. Bioulac-Sage, C. Balabaud, and J. Zucman-Rossi, “Subtype classiﬁcation of hepatocellular adenoma,” Digestive Surgery, vol. 27, no. 1, pp. 39–45, 2010. [4] S. F. Altekruse, K. A. McGlynn, and M. E. Reichman, “Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005,” Journal of Clinical Oncology, vol. 27, no. 9, pp. 1485–1491, 2009. [5] M. B. Thomas, D. Jaﬀe, M. M. Choti et al., “Hepatocellular carcinoma: consensus recommendations of the national cancer institute clinical trials planning meeting,” Journal of Clinical Oncology, vol. 28, no. 25, pp. 3994–4005, 2010. [6] I. R. Wanless, C. Mawdsley, and R. Adams, “On the patho- genesis of focal nodular hyperplasia of the liver,” Hepatology, vol. 5, no. 6, pp. 1194–1200, 1985. [7] S. Rebouissou, P. Bioulac-Sage, and J. Zucman-Rossi, “Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma,” Journal of Hepatology, vol. 48, no. 1, pp. 163–170, 2008. [8] S. Zheng, O. W. Cummings, R. Saxena et al., “Clonality and TP53 mutation analysis of focal nodular hyperplasia of the liver,” American Journal of Clinical Pathology, vol. 134, no. 1, pp. 65–70, 2010. [9] B. N. Nguyen, J. F. Fle´jou, B. Terris, J. Belghiti, and C. Degott, “Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms,” American Journal of Surgical Pathology, vol. 23, no. 12, pp. 1441–1454, 1999. [10] Y. W. Chen, Y. M. Jeng, S. H. Yeh, and P. J. Chen, “p53 gene and Wnt signaling in benign neoplasms: β-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia,” Hepatology, vol. 36, no. 4, pp. 927–935, 2002. [11] P. Bioulac-Sage, S. Rebouissou, A. Sa Cunha et al., “Clinical, morphologic, and molecular features deﬁning so-called telangiectatic focal nodular hyperplasias of the liver,” Gas- troenterology, vol. 128, no. 5, pp. 1211–1218, 2005. [12] S. Rebouissou, G. Couchy, L. Libbrecht et al., “The β-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules,” Journal of Hepatology, vol. 49, no. 1, pp. 61–71, 2008. [13] A. Iyer, M. E. Robert, C. B. Bifulco, R. R. Salem, and D. Jain, “Diﬀerent cytokeratin and neuronal cell adhesion molecule staining patterns in focal nodular hyperplasia and hepatic adenoma and their signiﬁcance,” Human Pathology, vol. 39, no. 9, pp. 1370–1377, 2008. [14] B. Spee, G. Carpino, B. A. Schotanus et al., “Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling,” Gut, vol. 59, no. 2, pp. 247–257, 2010. [15] L. Libbrecht, R. De Vos, D. Cassiman, V. Desmet, R. Aerts, and T. Roskams, “Hepatic progenitor cells in hepatocellular adenomas,” American Journal of Surgical Pathology, vol. 25, no. 11, pp. 1388–1396, 2001. [16] K. A. Mitchell and D. Jain, “Diagnostic approach to needle biopsies of hepatic mass lesions,” Diagnostic Histopathology, vol. 14, no. 12, pp. 598–608, 2008. [17] D. Ha¨ussinger, “Liver glutamine metabolism,” Journal of Parenteral and Enteral Nutrition, vol. 14, no. 4, pp. 56S–62S, 1990. [18] Z. D. Burke and D. Tosh, “The Wnt/β-catenin pathway: master regulator of liver zonation?” BioEssays, vol. 28, no. 11, pp. 1072–1077, 2006. [19] L. Barthelmes and I. S. Tait, “Liver cell adenoma and liver cell adenomatosis,” HPB, vol. 7, no. 3, pp. 186–196, 2005. Pathology Research International [20] V. Paradis, A. Benzekri, D. Darge´re et al., “Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma,” Gastroenterology, vol. 126, no. 5, pp. 1323–1329, 2004. [21] Y. R. Cai, L. Gong, X. Y. Teng et al., “Clonality and allelotype analyses of focal nodular hyperplasia compared with hepatocellular adenoma and carcinoma,” World Journal of Gastroenterology, vol. 15, no. 37, pp. 4695–4708, 2009. [22] O. Farges and S. Dokmak, “Malignant transformation of liver adenoma: an analysis of the literature,” Digestive Surgery, vol. 27, no. 1, pp. 32–38, 2010. [23] O. Bluteau, E. Jeannot, P. Bioulac-Sage et al., “Bi-allelic inactivation of TCF1 in hepatic adenomas,” Nature Genetics, vol. 32, no. 2, pp. 312–315, 2002. [24] K. Yamagata, N. Oda, P. J. Kaisaki et al., “Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3),” Nature, vol. 384, no. 6608, pp. 455– 458, 1996. [25] Y. Reznik, T. Dao, R. Coutant et al., “Hepatocyte nuclear factor-1α gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity- onset diabetes of the young (MODY)3 families,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 3, pp. 1476–1480, 2004. [26] J. Zucman-Rossi, E. Jeannot, J. T. Van Nhieu et al., “Genotype-phenotype correlation in hepatocellular ade- noma: new classiﬁcation and relationship with HCC,” Hep- atology, vol. 43, no. 3, pp. 515–524, 2006. [27] P. Bioulac-Sage, S. Rebouissou, C. Thomas et al., “Hepa- tocellular adenoma subtype classiﬁcation using molecular markers and immunohistochemistry,” Hepatology, vol. 46, no. 3, pp. 740–748, 2007. [28] S. Rebouissou, M. Amessou, G. Couchy et al., “Frequent in-frame somatic deletions activate gp130 in inﬂammatory hepatocellular tumours,” Nature, vol. 457, no. 7226, pp. 200– 204, 2009. [29] P. Bioulac-Sage, H. Laumonier, G. Couchy et al., “Hepato- cellular adenoma management and phenotypic classiﬁcation: the Bordeaux experience,” Hepatology, vol. 50, no. 2, pp. 481– 489, 2009. [30] A. Gru, R. K. Pai, and E. M. Brunt, “Clinicopathologic and molecularcharacterization of hepatocellular adenomas (HCA) and focal nodular hyperplasias (FNH),” Modern Pathology. In press. [31] P. Hytiroglou, Y. N. Park, G. Krinsky, and N. D. Theise, “Hepatic precancerous lesions and small hepatocellular car- cinoma,” Gastroenterology Clinics of North America, vol. 36, no. 4, pp. 867–887, 2007. [32] M. Kojiro, I. R. Wanless, V. Alves et al., “Pathologic diagnosis of early hepatocellular carcinoma: a report of the Inter- national Consensus Group for Hepatocellular Neoplasia,” Hepatology, vol. 49, no. 2, pp. 658–664, 2009. [33] V. Paradis, I. Bie`che, D. Darge`re et al., “Molecular proﬁling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index,” American Journal of Pathology, vol. 163, no. 2, pp. 733–741, 2003. [34] S. W. Nam, J. Y. Park, A. Ramasamy et al., “Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression proﬁling,” Hepatology, vol. 42, no. 4, pp. 809– 818, 2005. [35] J. M. Llovet, Y. Chen, E. Wurmbach et al., “A molecular signature to discriminate dysplastic nodules from early hep- atocellular carcinoma in HCV cirrhosis,” Gastroenterology, vol. 131, no. 6, pp. 1758–1767, 2006.